Jane Street Group LLC Has $145,000 Stock Holdings in Solid Biosciences Inc. (NASDAQ:SLDB)

Jane Street Group LLC decreased its position in Solid Biosciences Inc. (NASDAQ:SLDB) by 20.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,810 shares of the company’s stock after selling 5,299 shares during the period. Jane Street Group LLC owned about 0.05% of Solid Biosciences worth $145,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of Solid Biosciences during the second quarter valued at approximately $392,000. Rhumbline Advisers bought a new stake in Solid Biosciences in the 2nd quarter valued at $191,000. Acadian Asset Management LLC bought a new stake in Solid Biosciences in the 2nd quarter valued at $379,000. American Century Companies Inc. raised its stake in shares of Solid Biosciences by 39.9% in the 2nd quarter. American Century Companies Inc. now owns 34,557 shares of the company’s stock valued at $196,000 after buying an additional 9,853 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Solid Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company’s stock worth $402,000 after acquiring an additional 5,287 shares during the period. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Trading Down 10.1 %

Shares of NASDAQ SLDB opened at $3.31 on Tuesday. Solid Biosciences Inc. has a 1 year low of $3.28 and a 1 year high of $15.05. The firm’s 50-day moving average is $4.88 and its 200-day moving average is $6.61. The firm has a market capitalization of $132.25 million, a PE ratio of -1.09 and a beta of 2.05.

Solid Biosciences (NASDAQ:SLDB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.12). As a group, equities research analysts anticipate that Solid Biosciences Inc. will post -2.85 earnings per share for the current fiscal year.

Insider Transactions at Solid Biosciences

In other Solid Biosciences news, COO David T. Howton sold 5,072 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $28,403.20. Following the transaction, the chief operating officer now owns 15,663 shares in the company, valued at approximately $87,712.80. This trade represents a 24.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Alexander Cumbo sold 11,114 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $62,238.40. Following the transaction, the chief executive officer now owns 38,484 shares in the company, valued at approximately $215,510.40. This trade represents a 22.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,848 shares of company stock worth $155,852 in the last three months. Insiders own 13.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. JPMorgan Chase & Co. cut their price target on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Truist Financial assumed coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a report on Monday, November 11th. Citizens Jmp raised shares of Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Friday. Nine equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Solid Biosciences presently has a consensus rating of “Buy” and an average target price of $15.30.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.